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Age-related macular degeneration (AMD) is a major cause of blindness in the developed world. Oxidative stress and inflammation
are implicated in AMD, but precise mechanisms remain poorly defined. Carboxyethylpyrrole (CEP) is an AMD-associated lipid
peroxidation product. We previously demonstrated that mice immunized with CEP-modified albumin developed AMD-like
degenerative changes in the outer retina. Here, we examined the kinetics of lesion development in immunized mice and the
presence of macrophages within the interphotoreceptor matrix (IPM), between the retinal pigment epithelium and photoreceptor
outer segments. We observed a significant and time-dependent increase in the number of macrophages in immunized mice
relative to young age-matched controls prior to overt pathology. These changes were more pronounced in BALB/c mice than
in C57BL/6 mice. Importantly, IPM-infiltrating macrophages were polarized toward the M1 phenotype but only in immunized
mice. Moreover, when Ccr2-deficient mice were immunized, macrophages were not present in the IPM and no retinal lesions were
observed, suggesting a deleterious role for these cells in our model. This work provides mechanistic evidence linking immune
responses against oxidative damage with the presence of proinflammatory macrophages at sites of future AMD and experimentally
demonstrates that manipulating immunity may be a target for modulating the development of AMD.
1. Introduction
Age-related macular degeneration (AMD) is the most com-
mon cause of legal blindness in the elderly population of
developed countries with over 300,000 newly diagnosed
patients per year in Europe and North America [1, 2]. It is
widely believed that AMD starts with the insidious, slowly
progressing “dry” form (dry AMD) and can later develop into
themore severe “wet” AMD,which advances very rapidly and
is characterized by abnormal development of blood vessels, a
process called choroidal neovascularization (CNV) [3, 4] that
affects the macular region of the retina and leads to loss of
central vision. In turn, dry AMD without CNV can proceed
to focal loss of the retinal pigment epithelium (RPE), termed
geographic atrophy (GA), which is accompanied by loss of
vision over these slowly expanding areas of RPE atrophy
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[5]. RPE loss or dysfunction renders the surrounding tissue
vulnerable to damage by reactive oxygen species and loss of
photoreceptor density ensues [6]. It has been recognized that
accumulation of debris below the RPE in the macula, also
known as drusen, is a risk factor for AMD. Identification of
complement factor proteins in drusen from AMD eyes [7],
coupled with genetic variation in several complement factor
genes in AMD patients [8–13], collectively implicates inflam-
mation as an important component in the pathophysiology of
this disease [14, 15]. For instance, it was recently demonstrated
that complement factor H (CFH) serves a protective role
in AMD by binding and inhibiting the inflammatory effects
of the lipid peroxidation product malondialdehyde (MDA)
[16].Therefore, dissecting the initiating events of outer retinal
inflammation during the early stages of AMD can lead to a
better understanding of its pathogenesis. Such findings will
enable the development of innovative immunotherapies that
can prevent inflammatory damage to retinal tissue and loss
of vision in a disease process that is estimated to increase in
prevalence by 50% by the year 2020 [17].
In the past decade, several novel therapeutic agents have
been identified as effective drugs to treat wet AMD, which
delay new blood vessel formation and improve vision [18].
However, there is no effective treatment for dry AMD to date.
In the pursuit of identifying the signals from the outer retina
that initiate inflammation and possibly involve the immune
system in AMD pathogenesis, we have evaluated immune
responses to carboxyethylpyrrole (CEP), a protein modifica-
tion that forms from an oxidation fragment of docosahex-
aenoic acid (DHA) [19], the most oxidizable of all long chain
polyunsaturated fatty acids. Studies have shown that AMD
donor eyes contain more CEP-modified proteins in the outer
retina and drusen than in age-matched controls [7]. CEP-
modified proteins and CEP autoantibodies are also more
abundant in AMD plasma than in control samples [19, 20].
Since DHA is abundant in the outer retina [21], where
the amalgamation of high oxygen tension and light pro-
vides an environment suitable for oxidative damage, our lab
has previously developed a murine model in which mice
immunizedwithCEP-modifiedmouse serum albumin (CEP-
MSA) develop a CEP-specific immune response which corre-
lates with dry AMD-like pathology when compared to age-
matched controls, including CEP autoantibodies, comple-
ment deposition in the Bruch’s membrane, and RPE damage
[22, 23]. To our knowledge, this is the first immune-mediated
mouse model of dry AMD in genetically unmanipulated ani-
mals and stems directly fromobservations in human patients.
Another component of the immune system that has
been implicated in AMD is the macrophage lineage [24, 25],
although the specific role of these innate immune cells at
different stages of AMDdisease progression is still controver-
sial. Within the retina, there are two sources of macrophages:
(1) microglia, bone marrow-derived resident macrophages
that are recruited to neural tissue during retinal development
and provide immunosurveillance in the inner retina, and
(2) circulating monocytes that can be recruited from the
blood vessels to sites of inflammation when needed by spe-
cific chemokines and cytokines. Independent of the source,
these cells can undergo a diverse program of differentiation
depending on the microenvironment that ultimately dictates
their effector functions [26, 27].Macrophages activated in the
presence of interferon-gamma (IFN-𝛾) become proinflam-
matory M1 macrophages, characterized by their production
of tumor necrosis factor alpha (TNF-𝛼) and interleukin-12
(IL-12) and are associated with tissue damage. On the other
hand, macrophages activated in the presence of IL-4 differ-
entiate into M2-type, marked by production of the immuno-
suppressive cytokine IL-10 and involved in tissue remodeling.
The CEP-MSA-induced changes in the outer retina that
provide a model for AMD afford the unique opportunity to
directly test the role of these cells in the disease process.
Our current study aims to characterize both the mag-
nitude and kinetics of development of retinal lesions and
macrophage involvement in the BALB/c and C57BL/6 (B6)
mouse strains at various intervals postimmunization (p.i.)
in young mice compared to age-matched controls, before
extensive retinal lesions are observed. Here we extend our
original study [22] by showing that CEP-MSA immunization
leads, in aged (old) BALB/c mice, to the end stage cardinal
feature of human dry AMD: loss of photoreceptor cells. This
major damage is the result of a low-grade but significant
inflammatory response in the retina prior to overt tissue
damage, which can be quantified in young mice. We have
identified M1 macrophages localized to the interphotore-
ceptor matrix (IPM) surrounding the photoreceptor outer
segments in close proximity to the RPE. These changes
occur in both BALB/c and B6 strains, but the kinetics are
different; BALB/c mice are more susceptible at a younger
age. We also detected elevated levels of the monocyte che-
moattractant Ccl2 in the retinas of CEP-immunized mice.
Moreover, 𝐶𝑐𝑟2−/− B6 mice immunized with CEP-MSA lack
macrophage recruitment, and retinal lesion development is
reduced or prevented. Since AMD is an age-related disease,
defining the progression of inflammatory cell recruitment
and development of AMD-like lesions at earlier stages of the
disease is essential in order to map the character and timing
of immune mechanisms that take place in our model and
correlate with development of pathology. This work clarifies
a long-standing question by defining a clear mechanistic
path that explains the role of inflammation in AMD: M1
macrophages are key factors in dry AMD pathogenesis. We
also provide experimental demonstration for the idea that
regulation of immune responses (in this case, inhibition of
macrophage recruitment) can be a target of therapy to prevent
the development of AMD.
2. Results
2.1. Magnitude and Tempo of Lesion Development and
Inflammatory Cell Recruitment. We have previously
described AMD-like lesions in wild-type (WT) B6 mice
immunized with CEP-MSA [22]. We now describe in detail
lesions in CEP-MSA-immunized mice on the BALB/c back-
ground, which are inherently albino. Importantly, but also
technically challenging, the severity of lesions increases
with time after immunization, and it can take for up to
12–24 months to observe signs of geographic atrophy
and photoreceptor cell loss, cardinal features of AMD































Figure 1: Immunization with CEP-MSA leads to overt retinal degeneration in aged mice that resembles geographic atrophy with loss of
photoreceptor cells, particularly in the BALB/c background. Histology of CEP-MSA versus naı¨ve BALB/c or C57BL/6 eyes at different time
points postimmunization.TheRPE is located at the lower part of each image.The dark arrows showmacrophage-like cells. CEP-MSABALB/c
mice show strong pathology since the early time points, starting with swollen RPE cells and leading to massive geographic atrophy at the late
time point, including complete loss of the photoreceptor cells. The kinetics of pathology in CEP-MSA B6 mice is slower, but eventually there
are focal lesions of the RPE such as vesiculation, as previously reported [21]. Representative images are shown (from 3–5 mice per group per
experiment; two or three independent experiments were performed for each strain). INL: inner nuclear layer; ONL: outer nuclear layer; ROS:
rod outer segment; RPE: retinal pigment epithelium. Images were obtained using a 63x oil objective, and the scale marker represents a 20𝜇m
length.
(Figure 1, Supplemental Figure S1 available online at
http://dx.doi.org/10.1155/2013/503725). The main purpose of
the current study was to determine the earliest time at which
significant differences between CEP-immunized and control
mice could be detected. The reasoning behind this approach
is to define the molecular and cellular mechanisms that take
place at the initial stages of disease, before there are gross
changes to the retina that could alter its function.These early
time points could also be critical for therapeutic intervention.
Eyes harvested at 40–90 days p.i. were defined as of early
recovery times, those harvested at 100–200 days p.i. were con-
sidered of intermediate recovery times, while those obtained
after day 200 p.i. were considered of late recovery times. Focal
lesions in the RPE and IPM consisting of vacuolization of
individual or groups of cells, pyknotic RPE cells, hypertrophic
RPE cells, and melanin engulfment by macrophages (only
possible in B6 mice), as well as darkly stained nuclei of
inflammatory (macrophage-like) cells in the RPE and IPM
were counted (refer to Methods for detailed scoring parame-
ters) (Figure 1). While significant damage can be observed in
the retina of aged (12–24 months old) control mice (mainly
thinning of the photoreceptor layer, Figure 1, Supplementary
Figure 1), noGApathology is seen inmice that did not receive
CEP immunization or in younger CEP-immunized mice.
Our data was analyzed with a three-factor analysis of
variance; the factors are (1) strain of mice (BALB/c versus
B6), (2) immunization status (naı¨ve versus immunized), and
(3) time of recovery of tissue (early versus intermediate)
(Figure 2). Pathology scores (defined as the summation
of retinal lesions and cellular infiltration) were higher in
BALB/c CEP-immunizedmice at both early and intermediate
recovery times but only higher in B6 CEP-immunized mice
at the intermediate recovery time (Figure 2(a)). To have a
representative and objective pathological score throughout
the retina, we focused on the number of IPM-infiltrating
cells present in close proximity to the RPE. Using routine
histopathology, it is not possible to distinguish different types
of monocyte lineage cells present in the outer retina (for
example, resident microglia versus macrophages recruited
from the circulation). For this reason in the description of
the results to follow, we will simply refer to the nonneu-
ral cells in the IPM as macrophages, since microglia are
distinguished mainly for their location within the central
nervous system. Careful examination of the lesions at these
early and intermediate recovery times demonstrated that a
distinct population of macrophages is present in the IPM
compartment near the RPE in these animals. Quantification
in plastic sections showed that CEP-immunized BALB/cmice














































































































Figure 2: Quantification of retinal pathology and macrophage infiltration in CEP-MSA-immunized mice. (a) Combined pathology score
per section (all kinds of lesions and IPM-infiltrating cells). The significant changes due to CEP-MSA immunization occur at the early time
point in the BALB/c background, whereas they occur at intermediate time points for B6 mice. (b) CEP-MSA immunization accelerates
IPM-infiltrating cell recruitment at early stages of AMD development, prior to major retinal damage. Mean values are shown; error bars
represent S.D. (∗) denotes statistically significant differences (𝑃 < 0.05). Data from one representative experiment was used for this analysis;
similar results were obtained in additional repeat experiments. (c) Haematoxylin & Eosin (H&E) staining of frozen sections confirmed the
accelerated macrophage recruitment associated with CEP-MSA immunization. 5 sections were scored per mouse, with 3 mice per group at
the intermediate time point (d 100–200 p.i.). Mean values are shown; error bars represent S.D.
have a significantly higher number of macrophages than
age-matched na¨ıve animals harvested at 40–100 days p.i.
(𝑃 = 0.023) as well as those harvested at 100–200 days p.i.
(𝑃 = 0.023) (Figure 2(b)). The same cellular quantification is
observed with H&E staining of frozen sections (Figure 2(c)).
When comparing IPM macrophages between the two time
points, BALB/c mice showed an increase in the number of
these cells in the early to intermediate recovery times in
both immunized and na¨ıve mice, but the magnitude was
significantly higher in immunized mice (𝑃 = 0.012). While
CEP-immunized B6 mice harvested at early recovery times
showed no significant differences in IPMmacrophages when
compared to naı¨ve B6 mice, immunized mice harvested at
intermediate time points had more IPM macrophages than
age-matched B6 na¨ıve controls (𝑃 = 0.023). Therefore,
the number of monocyte-lineage cells present in the IPM
increases over time in CEP-immunized B6 mice to reach
significant numbers by the intermediate recovery times.
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2.2. Enhanced Immune-Mediated AMD-Like Pathology Is Spe-
cific to Genetic Background rather than Light Damage. Na¨ıve
BALB/c mice contained more macrophages in the IPM than
age-matched na¨ıve B6 mice (𝑃 < 0.01), and immunized
BALB/cmice show higher number of IPMmacrophages than
immunized B6 mice as well (𝑃 < 0.01). This difference
is also evident in the number of RPE lesions, which are
higher in BALB/c mice than in B6 mice, regardless of
immunization status. To test the possibility that photosensi-
tivity in the BALB/c albino mice [28] could be responsible
for the differences in outer retinal lesion development and
macrophage presence when compared to B6 mice, we immu-
nized albino B6 mice (B6(Cg)-𝑇𝑦𝑟𝑐−2𝐽/𝐽 or 𝑇𝑦𝑟−/− mice,
which lack the tyrosinase enzyme) and compared them to
age-matched na¨ıve 𝑇𝑦𝑟−/− mice as well as to corresponding
BALB/c and WT-B6-immunized and naı¨ve mice at 40–90
days p.i. The results from these comparisons showed that
both macrophages in the outer retina and development of
retinal lesions observed in𝑇𝑦𝑟−/−mice are comparable toWT
B6 and do not show the enhanced cellular recruitment, RPE
hypertrophy, and ROS vacuolization present in BALB/c mice
at the early time points, regardless of immunization status
(Figure 3(a)). Quantification analysis of pathological changes
per section supports these observations (Figure 3(b)). This
suggests that the differences in inflammatory cells present in
the outer retina and AMD-like pathology observed between
the BALB/c and the B6 strains are not due to photosensitivity
in the albino mice because of lack of pigmentation, but
instead they are specific to genetic background, possibly due
to differences in the immune responses against CEP-MSA
between the mice or to inherent differences in RPE function
and/or local oxidative damage responses in the retina.
2.3. Inflammatory Cells Surround the Retina of CEP-MSA-
Immunized Mice. Because inflammation associated with
macrophages present in the IPM seems to play a role in the
retinal pathology observed in CEP-MSA-immunized mice,
we performed immunohistochemical (IHC) analysis using
cell surface immune markers for the identification of the
specific macrophages present in the retina, generally, and to
the IPM region, specifically. A large number of CD45+ (a
pan-leukocyte marker) cells were observed in the choroid of
immunized mice compared to controls (Supplementary Fig-
ure 2), indicating that CEP immunization leads to increased
ocular inflammation. In terms of specific cell subsets, we
observed only a few CD3+ and CD19+ cells in the outer
retina, suggesting that both T cells and B cells are largely
absent from the site of retinal lesions (data not shown).
In contrast, there were substantial numbers of choroidal
CD11b+, F4/80+, and CD68+ cells surrounding the retinas
of BALB/c CEP-MSA-immunized mice and not of naı¨ve
controls (data not shown). Similar findings were observed in
B6 immunized animals at late recovery times when lesions
are present.
2.4. Proinflammatory M1Macrophages Are Present in the IPM
at Early Recovery Times in Mice Immunized with CEP-MSA.
Immunofluorescence staining identified retinal CD11b+,
F4/80+, and CD68+ cells in mice immunized with CEP-
MSA, suggesting the potential role of macrophages in the
development of disease in thismodel.Wewere able to localize
a significant number of these macrophages in the RPE and
IPM using nuclear counterstaining with DAPI (Figure 4(a),
Supplementary Figure 3). This correlates with the location of
themacrophages identified by histopathology using toluidine
blue and H&E staining that are mostly observed in proximity
with vacuolization and lesions of RPE and photoreceptors.
In order to determine the specific class and activation status
of these macrophages, we performed intracellular stains
for Tumor Necrosis Factor-alpha (TNF-𝛼) and Interleukin-
12 (IL-12) production, which identify M1 macrophages,
versus IL-10 production, a hallmark of M2 macrophage
differentiation. We observed both TNF+ and IL-12+ cells
within the IPM of CEP-MSA-immunized mice, but IL-10
staining was negative, indicating the presence of activated
M1 macrophages in the pathological regions of immunized
mice only (Figure 4(b)). To substantiate the IHC results,
we performed mRNA quantification on IPM-infiltrating
macrophages isolated by laser capture. These data confirmed
that detectable levels of M1 marker genes (IL-6, TNF-𝛼,
and IL-1𝛽) were observed only in CEP-immunized mice,
whereas IL-10 expression was not detected (Figure 4(c)).
Expression of Arg1, another M2 marker, was not elevated in
CEP-immunized mice. Interestingly, we also observed CEP-
associated increased expression of Ccl2, a monocyte che-
moattractant that has been implicated in AMD, suggesting
that the Ccl2/Ccr2 axis may play a role in CEP-induced
pathology. These data strongly suggest that M1 macrophages
are primarily associated with the lesions we observe in the
outer retina and may be the main effectors of the inflamma-
tory response observed in this model.
2.5. Macrophage Recruitment into the Outer Retina of CEP-
MSA-Immunized Mice Is Necessary for the Induction of Dis-
ease. To directly test the role of macrophage recruitment
into the IPM and development of outer retinal lesions we
immunizedCcr2-deficientmice on the B6 background.These
mice have a defect in chemokine signaling and show poor
recruitment of inflammatory cells into sites of inflammation.
In addition, it has been previously shown that disruption of
chemokine signaling to macrophages in these Ccr2 knockout
mice can have a deleterious effect on the integrity of the
retina in aged mice (2 years and older) [29]. While Ccr2
deficiency did not affect the levels of anti-CEP antibody titers
in young immunized mice (Figure 5(a)), 𝐶𝑐𝑟2−/− animals
showed no increase of IPM-infiltratingmacrophages or outer
retinal lesions in immunizedmice compared to those in naive
age-matched controls at late recovery times (Figure 5(b)).
This observation strongly suggests that macrophages, mainly
recruited by Ccl2, play a causative role in the induction of
tissue damage in this model.
3. Discussion
Immunization of mice with CEP-MSA provides a valuable
model to study dry AMD from an immunological per-
spective, helping to dissect the immune system’s role in





































































Figure 3: Immune-mediated cellular infiltration and development of outer retinal lesions are specific to genetic background and pigment
independent. (a) Histology of CEP-MSA albino B6 mice compared toWT BALB/c andWT B6 at the early time point. Representative images
are shown (from 3–5 mice per group per experiment; two or three independent experiments were performed for each strain). INL: inner
nuclear layer; ONL: outer nuclear layer; ROS: rod outer segment; RPE: retinal pigment epithelium. Images were obtained using a 63x oil
objective, and the scale marker represents a 20 𝜇m length. (b) Quantification shows the lack of pathology at early time points in albino B6
mice, similar to WT B6 and in contrast to WT BALB/c mice. Mean values are shown; error bars represent S.D.
the development of disease. Studies presented here link
the AMD-like histopathological changes with the presence
of macrophages in the outer retina during early stages of
disease, suggesting that macrophages are involved in the
underlying pathology. Notably, our data suggest that BALB/c
mice tend to be more sensitive to immunization with CEP-
MSA than B6mice by having a greater magnitude and earlier
significant difference of inflammatory cells in the IPM when
compared to age-matched controls. In addition, dry AMD-
like pathology, such as RPE cell hypertrophy, vacuolization
of RPE and ROS, and RPE cell pyknosis, is also found at
greater magnitude and arises earlier following immunization
in the BALB/c mice. We also show that old CEP-immunized
BALB/c mice develop photoreceptor cell loss. This suggests
that future studies using this model would benefit from
a more rapid and amplified immunopathological effect in
BALB/c mice than in B6 mice, yielding results as early as 40–
100 days postimmunization.
Even if BALB/c mice show an earlier significant response
to immunization with CEP-MSA than age-matched B6 mice,
it is important to stress that CEP-immunized mice contain
larger numbers of macrophages in the IPM and AMD-like
pathology than na¨ıve controls in both strains. Furthermore,
our data showed no statistically significant differences
between the two strains through time. This suggests that
any age-related changes seen in immunized mice observed
during the early stages of disease are of comparable magni-
tude regardless of strain, but that the higher number of
macrophages present in the IPM of BALB/c mice makes it
technically easier for quantification of disease onset. In other
words, the reason that there seems to be no early differences
in na¨ıve versus CEP-MSA mice on the B6 background is
because the actual number of IPM-infiltrating cells is too
low at that point to achieve statistical significance.
Differences between these two strains could also be
attributed to background-specific (genetic and/or immune)
mechanisms or to the reduced melanin levels in BALB/c
mice. B6 mice are prone to develop T helper type 1 (Th1)
responses, whereas BALB/c are Th2-prone. On the other
hand, it has been shown that melanin in the RPE provides
protection from light damage [30]. By showing that albino B6
(𝑇𝑦𝑟−/−) mice have comparable inflammatory cell numbers
in the IPM and AMD-like pathology with WT B6 mice in a
much less robust form than BALB/c mice, the possibility that
light damage largely contributes to pathology is less likely.
Indeed, it has been previously shown that B6 (𝑇𝑦𝑟−/−) are































































Figure 4: CEP-MSA immunization leads to M1 (TNF-𝛼, IL-12 producing) macrophage recruitment and activation in the subretinal space.
(a) Frozen sections followed by immunostaining and confocal microscopy. Surface marker stains were used to identify macrophages as the
infiltrate cells. F4/80+ and CD68+ cells are absent from the RPE of naive mice, but they are found in CEP-MSA-immunized BALB/c and
B6 mice. (b) Intracellular stains for TNF-𝛼, IL-12, and IL-10 production were used to determine the phenotype of the activated macrophages
observed in CEP-MSA BALB/c mice at the intermediate recovery time. IgG2b was used as isotype control. Representative images are shown
(from 3–5 mice per group per experiment; two or three independent experiments were performed for each strain). INL: inner nuclear layer;
ONL: outer nuclear layer; ROS: rod outer segment; RPE: retinal pigment epithelium; CHO: choroid. The scale marker represents a 20𝜇m
length. (c) Infiltrating macrophages from B6 mice were isolated by laser microdissection, and RNA was obtained for qPCR analysis of gene
expression. Relative mRNA (in arbitrary units) was calculated using the 2−ΔCt method with Actin as the calibrator gene. Transcripts for M1
marker genes (IL-1𝛽, TNF, and Ccl2) were detectable in 3 out of 5 CEP-MSA-immunized mice but were not present in CFA age-matched
controls (𝑛 = 4). M2 marker expression did not correlate with CEP immunization: IL-10 was completely absent, whereas the levels of Arg-1
did not increase. Results are representative of at least two independent laser capture experiments.






































Figure 5: Ccr2 chemokine receptor signaling is required for macrophage recruitment to the outer retina after CEP-MSA immunization. (a)
Anti-CEP antibody titers were examined following immunization ofWT versus𝐶𝑐𝑟2−/− B6mice (𝑛 = 5). Na¨ıve mice have no anti-CEP titers.
Mean values are shown; error bars represent S.D. (b) Retinal pathology scores for the indicated groups at the late time point (day 200+ p.i.;
𝑛 = 3). (∗) denotes statistically significant difference (𝑃 < 0.05); ns: not significant. Data from one representative experiment was used for
this analysis; similar results were obtained in a separate independent experiment.
not vulnerable to light damage [31]. Therefore, we believe
that at least one major reason for the observed kinetic and
quantitative differences is the number of inflammatory cells
in the outer retinas of BALB/c mice. Whether there are sig-
nificant differences in endogenous CEP levels in the retinas of
these mice, inherent differences in RPE function and/or local
oxidative damage responses in the retina, or the particular
contribution of specific adaptive immunity pathways, is an
aspect under current investigation in our laboratory.
This work also describes in detail the differences in sub-
retinal macrophages between these two widely used mouse
strains. While many macrophage-like cells are present in the
subretinal space of young naı¨ve BALB/c mice, we have not
been able to successfully identify these cells based on surface
marker expression. The true nature of these baseline retinal
macrophages in BALB/c mice remains unknown. Impor-
tantly, we only found subretinal CD11b+/F4/80+/CD68+
macrophages in CEP-MSA-immunized but not naive mice
of either strain. A previous study has shown the presence of
these macrophage-like cells in WT B6 mice but only after 20
months of age [32]. Because CEP-MSA immunization leads
to the presence of these macrophages in younger mice, we
believe that this is additional confirmation of the validity
of our model in accelerating an endogenous aging-related
process. Thus, the CEP model provides an ideal setting to
study different subpopulations of retinal macrophages.
The controversial role suggested for macrophages in
AMD stems primarily from the use of gene knockout mice
as well as an acute model for choroidal neovascularization
(CNV) that has been widely (and successfully) used tomimic
wet AMD. For instance, the assertion that macrophages
are antiangiogenic comes mostly from studies using laser-
induced CNV [33], which is actually an acute wound healing
response, not a chronic pathological state progressing from a
previously established disease state, such as humanwetAMD.
A further complication involves the two different forms of
AMD: macrophages could have different roles in dry versus
wetAMD. It is important to stress that the laser-inducedCNV
model is a completely different system from our CEP model
of dry AMD, and findings in one model will not necessarily
be directly comparable to the other.
The initial evidence linking macrophages with AMD
came from the analysis of mice deficient in macrophage che-
mokine signaling components (𝐶𝑐𝑙2−/− and 𝐶𝑐𝑟2−/− mice)
which show retinal defects similar to AMD with advanced
age (2-year-old mice or older), including spontaneous CNV
and “drusen” formation [29]. However, subsequent work by
Luhmann et al. (2009) [32] revealed that these findings were
in fact an artifact due subretinal macrophage accumulation
and that any AMD-like pathology in 𝐶𝑐𝑙2−/− mice was
most likely due to aging alone. An additional problem with
the knockout mice mentioned previously and their use as
AMD models is the fact that these strains were found to
include a known mutation (rd8) that by itself results in
retinal degeneration [34, 35]. Therefore most, if not all, the
previously published papers using these strains must be
reevaluated in that context.
However, there is still acceptable evidence associating
macrophages with AMD. For example, young macrophages
inhibit CNV in the laser-induced model of wet AMD,
but their antiangiogenic potential is reduced with age as
they switch to an M2 phenotype [33]. More recently, it
has been shown that microglia can induce RPE cells to
produce proinflammatory cytokines and chemokines [36].
However, information is lacking to clarify the pathological
role of macrophages at different stages of the AMD disease
process, particularly at the time of onset of dry AMD
before the transition to CNV. The presence of subretinal
CD11b+/F4/80+/CD68+ macrophages in CEP-MSA immu-
nized mice we show here is similarly reported in a recent
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paper by a different group [37]. In addition, we showed that
these macrophages were M1 polarized. This suggests a strong
causal link between the M1 macrophages and outer retinal
lesions.
In the original publication of our model, it was suggested
that macrophages were present as a result of tissue damage
and were not likely to cause disease [22]. The rationale for
this conclusion was the fact that many lesions occurred in
the absence of these cells. However, that original paper did
not go into detail on the characterization of these cells.
Missing from the first study and addressed in this paper
are three key parameters that now lead to the interpretation
that there is a causal relationship between M1 macrophages
and dry AMD-like pathology: (i) kinetics and magnitude
(quantification) of macrophage infiltration into the IPM
relative to lesion development; (ii) activation status of the
observedmacrophages; (iii) how are the cells being recruited?
This current study provides evidence for the first time that the
early involvement of M1 macrophages occurs in animals that
are predisposed to develop retinal lesions.We also provide the
mechanism for recruitment of these cells, as Ccl2 is elevated
in retinas of CEP-immunized mice, and its receptor, Ccr2, is
required for macrophage infiltration into the IPM.
While we cannot completely rule out at this time that
the M1 macrophages present in the IPM of CEP immunized
mice are actually microglia migrating from the inner retina,
it is likely that these cells come from the blood because of
the systemic nature of our immunization protocol; retinal
microglia are present at their normal inner retina location
in Rag-deficient mice that do not develop lesions upon CEP-
MSA immunization [22]. Furthermore, this model relies on
the endogenous accumulation of CEP adducts in the outer
retina, which should occur at equivalent rates in immunized
versus naı¨ve mice, allowing resident microglia an equal
access to the CEP antigen. A more definitive distinction of
the original source of these cells awaits the development
of microglia-specific and/or macrophage-specific markers.
Regardless, our work confirms the critical role of bone-
marrow-derived macrophages in the development of retinal
degeneration and provides an excellent platform to further
characterize this process.
As mentioned previously, we are aware that both 𝐶𝑐𝑟2−/−
and𝐶𝑐𝑙2−/−mice develop AMD-like pathology with age [29],
even though the recent work by Luhmann et al. [32, 34] has
challenged this notion, at least for 𝐶𝑐𝑙2−/− mice. A major
difference between these other studies and ours is that our
model allows us to focus on the evaluation of relatively young
animals following immunization with CEP-MSA, in contrast
to the retinal lesions described previously that develop in the
older knockout animals; we analyzed mice before 12 months
of age, the na¨ıve𝐶𝑐𝑟2−/−mice develop retinal pathology after
18–20months.Therefore, it would be difficult tomake a direct
comparison with our study, but it provides the opportunity
to explore new mechanisms that link immunity to AMD.
𝐶𝑐𝑟2
−/− mice do not lack ocular macrophages, just defective
(or delayed) age-related recruitment (to the choroid). In fact,
as shown by Luhmann et al. 2009 [32], “old” 𝐶𝑐𝑙2−/− mice
(which closely resemble the Ccr2 macrophage phenotype)
have increased macrophage recruitment to the subretinal
space (the same area in which we observe macrophage
infiltration in CEP-MSA mice) when compared to wild type,
showing that a defective Ccl2/Ccr2 axis does not necessarily,
by itself, preclude retinal infiltration of macrophages. While
there is certainly a possibility that the observed pathology in
CEP-immunized WT mice may not be due to macrophages,
we think the𝐶𝑐𝑟2−/− data in this paper answers that question:
if macrophages did not play a detrimental role in our model
(if the retinal lesions in CEP-MSA mice were macrophage
independent) then we should have observed some pathology
in the immunized 𝐶𝑐𝑟2−/− mice, which we did not. Because
the 𝐶𝑐𝑟2−/− mice still develop CEP antibodies similar to WT
(indicative of an effective adaptive immune response), theM1
phenotype of subretinal macrophages as well as the temporal
relationship between macrophage infiltration and retinal
lesions (macrophage recruitment precedes lesion develop-
ment), we believe that our interpretation that macrophages
are detrimental in our model is justified.
It is tempting to hypothesize that there could be two
different populations of macrophages involved in the AMD
disease process: one being early “harmful” M1 and the
other being the “protective” late M2, which in turn may
contribute to CNV (once disease has progressed sufficiently).
We believe that our data is representative of the role of
early M1 macrophages and provides a nice platform to study
early events in the development of AMD. This does not
exclude the idea that later cellular involvement may include
M2 macrophages that could be important for resolution of
disease, suggested in the published studies looking at aged
Ccr2/Ccl2 knockout mice [29, 32]. In fact, it was recently
shown in a retinal neuropathy injury model that IL-10-
producing (M2)macrophages have a protective role [38].The
balance between M1 and M2 at different ages may actually
dictate the damaged versus repaired tissue status of the retina.
To support this notion, a recent paper analyzing humanAMD
eyes showed that AMD correlated with increased M1/M2
ratios, whereas normal aging eyes hadmoreM2macrophages
[39]. In the context of the retina, CEP tilts the balance toward
the M1 pathway for its role in inflammation-induced GA.
The enhanced presence of proinflammatorymacrophages
in our model offers new opportunities to investigate their
role and function in AMD pathogenesis, as well as the
immunological signals and inflammatory agents behind their
activation and recruitment to the outer retina, a tissue histor-
ically thought of as an immunosuppressive environment. We
believe that innovative immunotherapies that target the low-
grade inflammatory responses at the early stages of ourmodel
can yield further promising information on the immune
mechanisms that take place in response to oxidative damage
in the retina.
4. Conclusions
An incomplete understanding of AMD pathogenesis pre-
vents the development of effective therapies. Current under-
standing of AMD recognizes oxidative stress and chronic
retinal inflammation as possible causative factors. Retinal
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macrophages have been recognized to have a role in AMD,
but their precise role (whether protective, damaging, or inci-
dental) remains controversial. Using our AMDmousemodel,
we observed significant macrophage retinal infiltration that
temporally preceded the onset of overt retinal pathology,
suggesting a causative role for macrophages in retinal
degeneration. Interestingly, mice with defective macrophage
recruitment (Ccr2-deficient mice) lack macrophage retinal
infiltrates and are devoid of AMD-like retinal pathology.
This work uncovers an important and detrimental role for
macrophages in the development of AMD. Such an under-
standing raises the possibility of exploring immune-modu-
lating therapy for the treatment or prevention of retinal
degeneration, especially in patients exhibiting early signs of
disease.
5. Materials and Methods
5.1. Mice. BALB/c wild-type mice, C57BL/6 wild-type mice,
and 𝐶𝑐𝑟2−/− and B6(Cg)-𝑇𝑦𝑟𝑐−2𝐽/J (B6-albino) mice were
obtained fromThe Jackson Laboratory. All mice were housed
in a room exposed to 300 lux (outside the cage) in a 12 hr
dark/light cycle. Protocols for use of experimental animals in
this study adhered to the ARVOStatement for theUse of Ani-
mals in Ophthalmic and Vision Research and were approved
by the Institutional Animal Care and Use Committee of the
University of Miami Miller School of Medicine.
5.2. Antigen. CEP-MSA was prepared from commercially
available mouse serum albumin (Sigma-Aldrich), which was
converted to CEP-modified MSA following previously pub-
lished procedures [40].
5.3. Immunizations. The CEP-MSA immunization protocol
has been described previously [22]. In summary, mice were
primed by hind leg injections of 200 𝜇g CEP-MSA in com-
plete Freund’s adjuvant (CFA; from DIFCO) at 6–10 weeks
of age. At day 10 postimmunization (p.i.), the mice were
challenged in the neck with 100 𝜇g CEP-MSA in incomplete
Freund’s adjuvant (IFA; from DIFCO), followed by a final
boost with 100 𝜇g CEP-MSA in CFA in the neck seven days
before harvest. Anti-CEP antibody titers at days 40–60 p.i.
were quantified by ELISA as previously described [22] and
used to determine efficiency of immunization. All immu-
nized mice were compared with age-matched na¨ıve, sham-
MSA, or CFA controls. There are no significant differences
among the control mice (with low to undetectable anti-CEP
titers) in terms of retinal pathology and are therefore used
interchangeably, depending on experimental setup.
5.4. Histology. Eyes were harvested at early (40–90 days),
intermediate (100–200 days), and late (over 200 days) recov-
ery times postimmunization (p.i.). Right eyes were used for
histology and were fixed in 2% paraformaldehyde and 2.5%
glutaraldehyde in 0.1M PO
4
buffer (pH = 7.4) overnight
and dehydrated in graded ethanol and propylene oxide.
After polymerization in a resin mixture containing Polybed
812 (Polysciences) and Araldite 502 (Polysciences), semithin
(0.7 𝜇m) sagittal sections of each eye were stained with
toluidine blue and analyzed for histopathology with light
microscopy using a Zeiss microscope (equipped with an
AxioCam digital camera) using a 63x oil-immersion lens.
5.5. Quantification of Lesions and Inflammatory Cells in the
IPM. Each individual mouse in this study was scored for
retinal pathology on a masked fashion, using 10 sections
of the right eye with at least 25–30𝜇m intervals between
each section. Scoring was divided in 2 subclasses: (1) the
retinal lesion count represents the sum of RPE areas showing
abnormal vesiculation, swelling, thinning, pyknosis, and cell
lysis; (2) inflammatory cells were defined as dark nuclear
stains of macrophage-like cells observed and counted only
within the interphotoreceptor matrix compartment at the
level of the photoreceptor outer segments and the apical
border of the RPE.The overall pathology score for each eye is
the sum of the two subclasses.The data is always presented as
pathology (cells or lesions or combined) per section.
5.6. Statistical Analysis of Retinal Pathology. Our data was
analyzed in the Biostatistics Department at the Bascom
Palmer Eye Institute with a three factor analysis of variance;
the factors are: (1) strain of mice (BALB/c versus B6), (2)
immunization status (naı¨ve versus immunized), and (3)
recovery time (early versus intermediate). A total of 3–5
mice were used in the analysis at each recovery time. At
least two independent experiments were performed for
each strain reported in this study. Repeat experiments with
similar results were analyzed separately because of the use of
independent batches of CEP-MSA.
5.7. Immunohistochemistry. Identification of inflammatory
cells in the IPM was done by immunostaining of frozen
sagittal sections from the corresponding left eye for each
animal. Following enucleation, eyes were embedded in OCT
compound (Sakura Finetek USA), frozen on dry ice, and
8 𝜇m sections were cut using a cryostat (−20∘C). Frozen
sections were collected on microscope slides. The sections
were fixed with 3% formaldehyde for 25min then pretreated
with a blocking solution containing 0.05% tween 20 and 3%
bovine serum albumin in PBS for 1 h at room temperature
to saturate nonspecific binding sites. The sections were then
incubated 1 h at room temperature with the primary antibody
diluted in PBS tween and 1% BSA. The following antibodies
were used for surface stains: rat anti-mouse CD11b, F4/80,
CD68, and CD45 (all from eBioscience). For intracellular
staining, we diluted the primary antibodies in saponin buffer.
The following antibodies were used for intracellular stains:
rat anti-mouse TNF-𝛼 (BD Bioscience), IL-12p70 (Endogen),
and IL-10 (BD Bioscience). Sections were then rinsed for
10min in PBS tween and incubated with 1 : 2000 goat anti-
rat Alexa Fluor 594 (Invitrogen) for 1 h at room temperature.
The sections were washed three times for 10min in PBS
tween and for 10min in PBS, coverslipped with Vectashield
with DAPI for nuclear counterstaining (Vector Laboratory)
and photographed in a Zeiss universal microscope (Carl
Zeiss, Oberkochen, Germany) equipped for incident-light
fluorescence and confocal microscopy.
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5.8. Laser Capture Microdissection of Outer RetinaMacropha-
ges. CFA or CEP-MSA-immunized mice were euthanized
in a CO
2
chamber, and their eyes were harvested for tissue
processing. Eyes were cryoprotected in 1.5% sucrose,
embedded in Tissue-Tek OCT compound (Sakura Finetek,
USA), and frozen. Cryostat sections, 12𝜇m thick, were
mounted on PEN-membrane slides (Leica). Sections were
then incubated in absolute ethanol and briefly stained for
H&E. Single infiltrating macrophages in interphotoreceptor
matrix were collected using Laser Microdissection System
LMD6000 (Leica). Total RNA was extracted using the
RNeasy mini kit (Qiagen) and reversely transcribed with
High-Capacity cDNA Archive Kit (Applied Biosystems).
cDNA was preamplified with Taqman PreAmp Master Mix
Kit followed by PCR amplifications of cDNA, using Taqman
probe-based gene expression assay (Applied Biosystems).
Relative mRNA (in arbitrary units) was calculated using the
comparative quantitationmethod of relative quantity (2−ΔCt),
with actin as the calibrator for each gene of interest. Primer
and probe sets were as follows: ActB, Mm00607939 s1,
IL-1𝛽, and Mm01336189 m1; TNF-𝛼, Mm00443258 m1;
IL-6, Mm00446190 m1; Ccl2, Mm00441242 m1; IL-10,
Mm99999062 m1; Arg1, Mm00475988 M1.
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